ZEO ScientifiX Strengthens Leadership Team With The Appointment of Dr. Peter Everts as Chief Scientific and Technology Officer
ZEO ScientifiX (OTCQB:ZEOX) has appointed Dr. Peter A. M. Everts as Chief Scientific and Technology Officer. Dr. Everts brings over 35 years of experience as a clinician, researcher, and executive, specializing in medical devices and biological therapies.
Prior to joining ZEO, he served as Chief Scientific Officer at EmCyte and Educational Program Director at Gulf Coast Biologics. He co-founded the Da Vinci Clinic in the Netherlands in 2010 and held senior leadership roles at Avance Medical. Dr. Everts earned his Ph.D. from the University of Utrecht and holds professorships at the University of Queensland and Max Planck University.
The appointment aims to accelerate innovation in biological therapeutics for regenerative medicine and advance the company's clinical trial portfolio. Ian Bothwell, Interim CEO and CFO, emphasized that this strategic addition reinforces ZEO's market position in the biologic medicine industry.
ZEO ScientifiX (OTCQB:ZEOX) ha nominato Dr. Peter A. M. Everts come Chief Scientific and Technology Officer. Il Dr. Everts porta con sé oltre 35 anni di esperienza come clinico, ricercatore ed esecutivo, specializzandosi in dispositivi medici e terapie biologiche.
Prima di unirsi a ZEO, ha ricoperto il ruolo di Chief Scientific Officer presso EmCyte e Direttore del Programma Educativo presso Gulf Coast Biologics. Ha co-fondato la Da Vinci Clinic nei Paesi Bassi nel 2010 e ha ricoperto ruoli di leadership senior presso Avance Medical. Il Dr. Everts ha conseguito il dottorato presso l'Università di Utrecht e detiene cattedre presso l'Università del Queensland e l'Università Max Planck.
La nomina mira ad accelerare l'innovazione nelle terapie biologiche per la medicina rigenerativa e a far progredire il portafoglio di studi clinici dell'azienda. Ian Bothwell, CEO e CFO ad interim, ha sottolineato che questa aggiunta strategica rinforza la posizione di mercato di ZEO nell'industria della medicina biologica.
ZEO ScientifiX (OTCQB:ZEOX) ha nombrado al Dr. Peter A. M. Everts como Director Científico y de Tecnología. El Dr. Everts aporta más de 35 años de experiencia como clínico, investigador y ejecutivo, especializado en dispositivos médicos y terapias biológicas.
Antes de unirse a ZEO, se desempeñó como Director Científico en EmCyte y como Director del Programa Educativo en Gulf Coast Biologics. Co-fundó la Clínica Da Vinci en los Países Bajos en 2010 y ocupó roles de liderazgo senior en Avance Medical. El Dr. Everts obtuvo su doctorado en la Universidad de Utrecht y tiene cátedras en la Universidad de Queensland y en la Universidad Max Planck.
La nominación tiene como objetivo acelerar la innovación en terapias biológicas para la medicina regenerativa y avanzar en el portafolio de ensayos clínicos de la empresa. Ian Bothwell, CEO y CFO interino, enfatizó que esta adición estratégica refuerza la posición de mercado de ZEO en la industria de la medicina biológica.
ZEO ScientifiX (OTCQB:ZEOX)는 Dr. Peter A. M. Everts를 최고 과학 및 기술 책임자로 임명했습니다. Everts 박사는 의료 기기 및 생물학적 치료를 전문으로 하는 임상 의사, 연구자 및 경영자로서 35년 이상의 경험을 가지고 있습니다.
ZEO에 합류하기 전, 그는 EmCyte에서 최고 과학 책임자로 재직했으며 Gulf Coast Biologics에서 교육 프로그램 이사로 활동했습니다. 그는 2010년에 네덜란드에서 다빈치 클리닉을 공동 설립했으며 Avance Medical에서 고위 리더십 역할을 수행했습니다. Everts 박사는 위트레흐트 대학교에서 박사 학위를 받았으며 퀸즐랜드 대학교와 막스 플랑크 대학교에서 교수직을 맡고 있습니다.
이번 임명은 재생 의학을 위한 생물학적 치료 혁신을 가속화하고 회사의 임상 시험 포트폴리오를 발전시키기 위한 것입니다. 임시 CEO 및 CFO인 Ian Bothwell은 이 전략적 추가가 생물학적 의약품 산업에서 ZEO의 시장 위치를 강화한다고 강조했습니다.
ZEO ScientifiX (OTCQB:ZEOX) a nommé Dr. Peter A. M. Everts en tant que Directeur Scientifique et Technologique. Le Dr. Everts apporte plus de 35 ans d'expérience en tant que clinicien, chercheur et cadre, se spécialisant dans les dispositifs médicaux et les thérapies biologiques.
Avant de rejoindre ZEO, il a été Directeur Scientifique chez EmCyte et Directeur de Programme Éducatif chez Gulf Coast Biologics. Il a co-fondé la Clinique Da Vinci aux Pays-Bas en 2010 et a occupé des postes de direction chez Avance Medical. Le Dr. Everts a obtenu son doctorat à l'Université d'Utrecht et détient des chaires à l'Université du Queensland et à l'Université Max Planck.
La nomination vise à accélérer l'innovation dans les thérapies biologiques pour la médecine régénérative et à faire avancer le portefeuille d'essais cliniques de l'entreprise. Ian Bothwell, PDG et CFO par intérim, a souligné que cet ajout stratégique renforce la position de marché de ZEO dans l'industrie de la médecine biologique.
ZEO ScientifiX (OTCQB:ZEOX) hat Dr. Peter A. M. Everts zum Chief Scientific and Technology Officer ernannt. Dr. Everts bringt über 35 Jahre Erfahrung als Kliniker, Forscher und Führungskraft mit, spezialisiert auf medizinische Geräte und biologische Therapien.
Vor seinem Eintritt bei ZEO war er Chief Scientific Officer bei EmCyte und Bildungsprogramm-Direktor bei Gulf Coast Biologics. Er co-gründete die Da Vinci Klinik in den Niederlanden im Jahr 2010 und hatte Führungspositionen bei Avance Medical inne. Dr. Everts erwarb seinen Ph.D. an der Universität Utrecht und hat Professuren an der Universität von Queensland und der Max-Planck-Universität.
Die Ernennung zielt darauf ab, die Innovation in biologischen Therapeutika für die regenerative Medizin zu beschleunigen und das klinische Studienportfolio des Unternehmens voranzutreiben. Ian Bothwell, Interims-CEO und CFO, betonte, dass diese strategische Ergänzung die Marktposition von ZEO in der biologischen Medizinbranche stärkt.
- Appointment of highly experienced executive with 35+ years in relevant medical and research fields
- Strategic enhancement of leadership team with expertise in biological therapies and regenerative medicine
- Addition of international research expertise through university collaborations
- None.
FORT LAUDERDALE, FL / ACCESS Newswire / February 18, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company focused on the research and development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine and the development and sales of biologic products used in topical aesthetic applications, today announced that it has appointed Peter A. M. Everts, Ph.D., as the Company's Chief Scientific and Technology Officer.
Dr. Everts has built a distinguished career of over 35 years as a clinician, researcher, and executive, with specialized expertise in medical devices and biological therapies used in orthobiology-msk, spine, chronic wound care, cardiac surgery, reconstructive surgery, facial aesthetics, hair regrowth, and other regenerative medicine applications.
Prior to joining ZEO, Dr. Everts served as Chief Scientific Officer at EmCyte Corporation and Educational Program Director at Gulf Coast Biologics, where he led research and development efforts focused on autologous biological protocols to improve patient outcomes in musculoskeletal and spine disorders. In 2010, Dr. Everts co-founded the Da Vinci Clinic in the Netherlands, where he served as Chairman of the Board of Directors, specializing in hyperbaric medicine and advanced biological therapies for complex chronic wound care. He also held senior leadership roles at Avance Medical (Switzerland), directing regenerative medicine and cell therapies for European and Middle East markets. His international collaborations with universities and research centers have contributed to significant advancements in the field.
Dr. Everts earned his Ph.D. in Medicine from the University of Utrecht, the Netherlands, and currently holds an Adjunct Professorship at the University of Queensland, Brisbane (Australia) and an International Professorship at Max Planck University, Indaiatuba (Brazil).
Dr Everts commented, "the opportunity to join the ZEO team is both exciting and rewarding as ZEO is committed to advancements in innovative biological therapeutics for regenerative medicine, based on safety and evidence-based data."
"We are excited to welcome Dr. Everts to the ZEO ScientifiX™ leadership team," said Ian Bothwell, Interim CEO and CFO of ZEO. "His vast experience and leadership will be instrumental as we continue to develop innovative biologic therapeutic products and seek to advance our clinical trial portfolio."
In addition, Mr. Bothwell added, "this strategic addition to ZEO's executive team underscores the Company's commitment to accelerating innovation, enhancing patient outcomes, and expanding the commercial potential of regenerative therapies. As investors seek to capitalize on the exponential growth of the biologic medicine industry, we believe that Dr. Everts' leadership will play a pivotal role in guiding the Company's scientific advancements and reinforcing its market position".
About ZEO ScientifiX, Inc.
ZEO ScientifiX is a clinical-stage biopharmaceutical company primarily focused on developing innovative biological therapeutics for regenerative medicine and the treatment of degenerative diseases. We are driven by a commitment to advance the frontiers of regenerative medicine and biologic therapeutics, delivering meaningful solutions for patients and providers worldwide. Our proprietary products, including (a) Zofin™, which are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and (b) Patient Pure X™ ("PPX™"), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood. During November 2024, the Company announced that it was launching the first planned collaborative product with Exotropin; "ZEO HAIR GROW™ Powered By Exotropin™", a proprietary topical physician formulated hair regrow system. The Company's proprietary products are manufactured in an FDA-registered, cGMP-compliant laboratory. To learn more, please visit https://zeoscientifix.com.
Forward-Looking Statements
Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will," "believes," "expects," "potential," or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. No assurances can be given that the Company will be successful in its research initiatives. In addition, no assurances can be given that our research initiatives will increase the price of our common stock to a level that is attractive to brokerage houses and institutional investors. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations, including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. ZEO has no intention and specifically disclaims any duty to update the information in this press release.
Contact Information
ZEO Investor Relations
Jacqueline Domenech
1-888-963-7881
IR@zeoscientifix.com
SOURCE: Zeo ScientifiX, Inc.
View the original press release on ACCESS Newswire
FAQ
What is Dr. Peter Everts' role at ZEO ScientifiX (ZEOX)?
What experience does Dr. Everts bring to ZEOX?
How will Dr. Everts' appointment impact ZEOX's business strategy?
What are Dr. Everts' academic credentials and affiliations?
